LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...
- Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers to CNS drug delivery - “Our discovery of a binding receptor for one of our capsid ...
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious ...
Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer brain metastasis Novel AAV5-derived capsid ...
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy - - Voyager to receive up-front consideration of $100 ...
- Receptor findings support potential for human translation of Voyager’s capsids and may help overcome barriers to CNS drug delivery - CAMBRIDGE, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Voyager ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback